High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy
- 266 Downloads
Real-world evidence focusing on medication switching patterns amongst direct oral anticoagulant (DOACs) has not been well studied. The objective of this study is to evaluate patterns of prescription switching in non-valvular atrial fibrillation (NVAF) patients initiated on a DOAC and previously naïve to anticoagulation (AC) therapy. Data was obtained from Truven Health MarketScan® Commercial and Medicare Supplemental database (2009–2013). AC naïve (those without prior anticoagulant use) NVAF patients initiated on a DOAC, with 6 months of continuous health plan enrollment before and after treatment initiation and maintained on continuous therapy for a minimum of 6 months were included. Of 34,022 AC naïve NVAF patients initiating a DOAC, 6613 (19.4%) patients switched from an index DOAC prescription to an alternate anticoagulant and 27,409 (80.6%) remained on the DOAC [age: 68.5 ± 11.7 vs. 67.1 ± 12.7 years, p < 0.001; males: 3781 (57.2%) vs. 17,160 (62.6%), p < 0.001]. Amongst those that switched medication, 3196 (48.3%) did so within the first 6 months of therapy. Overall, 2945 (44.5%) patients switched to warfarin, 2912 (44.0%) switched to another DOAC and 756 (11.4%) switched to an injectable anticoagulant. The highest proportion of patients switched from dabigatran to warfarin (N = 2320; 42.5%) or rivaroxaban (N = 2252; 41.3%). The median time to switch from the index DOAC to another DOAC was 309.5 days versus 118.0 days (p < 0.001) to switch to warfarin. In NVAF patients newly initiated on DOAC therapy, one in five patients switch to an alternate anticoagulant and one of every two patients do so within the first 6 months of therapy. Switching from an initial DOAC prescription to traditional anticoagulants occurs as frequently as switching to an alternate DOAC.
KeywordsDirect oral anticoagulants Atrial fibrillation Switching patterns Switching therapy Rivaroxaban Dabigatran Apixaban
Department of Pharmacy Systems, Outcomes and Policy (PSOP) and the Center for Pharmacoepidemiology and Pharmacoeconomic Research (CPR) at University of Illinois at Chicago for providing material support to the research. Dr. Galanter is supported by grant U19HS021093 from the Agency for Healthcare Research and Quality. Dr. Nutescu is supported by the National Heart, Lung, And Blood Institute Award Number K23HL112908 and the National Institute on Minority Health and Health Disparities Award Number U54MD010723. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Agency for Healthcare Research and Quality.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AG, Cutler NR, Hiatt WR, Halperin JL, The Antithrombotic Trials Leadership and Steering Group (2012) comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? J Thromb Haemost 10(12):2621–2624CrossRefPubMedGoogle Scholar
- 6.Barnes GD, Ageno W, Ansell J, Kaatz S, Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis (2015) Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 13:1154–1156CrossRefPubMedGoogle Scholar
- 10.Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, Choudhry NK (2014) Patterns of initiation of oral anticoagulants in patients with atrial fibrillation-quality and cost implications. Am J Med 127(11):1075–1082.e1CrossRefPubMedGoogle Scholar
- 13.Schiavoni M, Margaglione M, Coluccia A (2017) Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre. Blood Transfus 31:1–6Google Scholar
- 16.Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P et al (2015) Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2(4):e150–e159CrossRefPubMedGoogle Scholar
- 17.Auyeung V, Patel JP, Abdou JK, Vadher B, Bonner L et al (2016) Anticoagulated patient’s perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy—study protocol for The Switching Study: a prospective cohort study. BMC Hematol 16(1):22CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Truven Health Analytics Health research data for the real world: the MarketScan Databases. Available at http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf
- 22.Truven Health Analytics Truven health analytics links clinical data with claims to enhance oncology outcomes research. Available at http://truvenhealth.com/news-and-events/press-releases/detail/prid/33/Truven-Health-Analytics-Links-Clinical-Data-with-Claims-to-Enhance-Oncology-Outcomes-Research